HC Wainwright reissued their buy rating on shares of Daré Bioscience (NASDAQ:DARE – Free Report) in a report published on Thursday, Benzinga reports. HC Wainwright currently has a $12.00 price target on the biotechnology company’s stock.
Separately, Maxim Group restated a “hold” rating on shares of Daré Bioscience in a research report on Wednesday, August 14th.
Read Our Latest Report on DARE
Daré Bioscience Trading Up 4.3 %
Daré Bioscience (NASDAQ:DARE – Get Free Report) last announced its quarterly earnings results on Monday, August 12th. The biotechnology company reported $1.52 earnings per share for the quarter, beating the consensus estimate of ($0.57) by $2.09. The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.60 million. On average, research analysts predict that Daré Bioscience will post -0.27 earnings per share for the current fiscal year.
Institutional Trading of Daré Bioscience
A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC lifted its position in Daré Bioscience, Inc. (NASDAQ:DARE – Free Report) by 2.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 778,700 shares of the biotechnology company’s stock after acquiring an additional 15,800 shares during the period. Renaissance Technologies LLC owned 9.25% of Daré Bioscience worth $262,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 6.70% of the stock is currently owned by hedge funds and other institutional investors.
About Daré Bioscience
Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.
Further Reading
- Five stocks we like better than Daré Bioscience
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- The How And Why of Investing in Oil Stocks
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Breakout Stocks: What They Are and How to Identify Them
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Daré Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daré Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.